US › Healthcare

Immutep Ltd ADR (IMMP)

US · Healthcare · Biotechnology

$0.32-3.09%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$10.6M

Revenue YoY

+513.7%

Net profit

$-34.9M

EPS

$0.00

EPS estimate

$0.00

Net margin

-328.8%

Key statistics

Market cap

$46.7M

Forward P/E

7.1

P/B

1.10

Book value

$0.30

EPS (TTM)

$-0.37

52-week high

$3.32

52-week low

$0.29

50-day MA

$0.39

200-day MA

$1.23

Beta

2.20

Analyst view

Analysts rate Immutep Ltd ADR a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $1.50.

Shareholding

Insiders

0.01%

Institutions

1.13%

Largest institutional holders

Fund	Stake
BlackRock Inc	0.03%
UBS Group AG	0.03%
JustInvest LLC	0.01%
Two Sigma Investments LLC	0.00%
XTX Topco Ltd	0.00%
TWO SIGMA SECURITIES, LLC	0.00%
Virtu Financial LLC	0.00%
LPL Financial Corp	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immutep Ltd ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.